This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Preview: Nu Skin Enterprises (NUS) Q3 Earnings Expected to Decline
by Zacks Equity Research
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Estee Lauder Maintain Momentum on Solid Travel Retail?
by Zacks Equity Research
Estee Lauder's (EL) strong online business and travel retail network are likely to drive growth. The company also benefits from a solid presence in emerging markets.
NUS vs. IPAR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NUS vs. IPAR: Which Stock Is the Better Value Option?
Avon's (AVP) Open Up Strategy to Drive Long-Term Growth
by Zacks Equity Research
Avon's (AVP) Open Up strategy keeps the company on track to attain its financial targets for 2021.
Nu Skin's Customer Base Bodes Well, Mainland China is a Worry
by Zacks Equity Research
Nu Skin (NUS) is battling headwinds in Mainland China that led to an unimpressive view for 2019. However, a rising customer base bodes well.
Nu Skin Down 12% in 3 Months, Mainland China is a Concern
by Zacks Equity Research
Nu Skin (NUS) is battling headwinds in Mainland China, stemming from the government's campaign to scrutinize offerings of direct selling and health products industries.
Nu Skin (NUS) Up 1.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin (NUS) Q2 Earnings In Line With Estimates, Sales Miss
by Zacks Equity Research
Headwinds in Mainland China were a drag on Nu Skin's (NUS) revenues and earnings in the second quarter of 2019.
Nu Skin Enterprises (NUS) Meets Q2 Earnings Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 0.00% and -1.53%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Is a Disappointment in Store for Nu Skin (NUS) Q2 Earnings?
by Zacks Equity Research
Nu Skin's (NUS) Q2 performance is likely to be hurt by the government campaign in Mainland China to inspect offerings of direct selling industries and health products.
Analysts Estimate Nu Skin Enterprises (NUS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NUS or IPAR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NUS vs. IPAR: Which Stock Is the Better Value Option?
Nu Skin Trims View on Anticipated Declines in Mainland China
by Zacks Equity Research
Nu Skin's (NUS) Q2 and 2019 results are likely to be hurt by weak performance in China, triggered by government's product review initiatives.
Nu Skin Gains from Product Launches, Currency Rates Hurt
by Zacks Equity Research
Nu Skin's (NUS) customer base rises steadily, courtesy of effective marketing strategies and launches. However, adverse impacts of currency rates are concerns.
Why Is Nu Skin (NUS) Down 25.1% Since Last Earnings Report?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin (NUS) Up 6% in a Month: Can It Maintain Momentum?
by Zacks Equity Research
Nu Skin (NUS) focuses on capturing greater market share through sales leaders. However, the company is battling currency headwinds.
Nu Skin (NUS) Beats on Q1 Earnings & Revenues, Q2 View Soft
by Zacks Equity Research
The performance can be attributed to Nu Skin's (NUS) technology and business expansion initiatives as well as customer acquisition and retention program.
Nu Skin Enterprises (NUS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's What You Must Note Ahead of Nu Skin (NUS) Q1 Earnings
by Zacks Equity Research
Nu Skin's (NUS) is likely to benefit from effective marketing programs, gains from social media and a solid sales leaders' network. These factors are set to drive customer count in Q1.
Nu Skin Boasts Customer Growth, Faces Weak Gross Margin
by Zacks Equity Research
Nu Skin (NUS) gains from an expanding customer base and prudent product launches. However, persistent decline in gross margin is a concern.
Estee Lauder's Buyouts & Robust Online Business Bode Well
by Zacks Equity Research
Estee Lauder's (EL) solid focus on buyouts, travel retail network, effective launches and strong online sales are impressive.
NUS vs. IPAR: Which Stock Is the Better Value Option?
by Zacks Equity Research
NUS vs. IPAR: Which Stock Is the Better Value Option?
Can Value Investors Consider Nu Skin (NUS) Stock Now?
by Nabaparna Bhattacharya
Nu Skin (NUS) stock may be a good choice for value-oriented investors right now from multiple angles.
Zacks.com featured highlights include: Materion, Boston Beer , Nu Skin, Darden and Comfort Systems
by Zacks Equity Research
Zacks.com featured highlights include: Materion, Boston Beer , Nu Skin, Darden and Comfort Systems
Coty Picks Up Steam, Stock Rallies 59% Since Q2 Results
by Zacks Equity Research
Coty's (COTY) Luxury unit continues to deliver a strong show. Also, acquisitions and e-commerce efforts bode well amid hurdles like soft Consumer Beauty segment.